Latest news with #ReynoldLemkins
Business Wire
05-08-2025
- Business
- Business Wire
Reynold Lemkins Drives Cross-Border Deep Tech Investment, Featured Prominently at Asia's Leading Capital and Innovation Forums
HONG KONG & MACAU--(BUSINESS WIRE)--Reynold Lemkins Group, a global investment firm known for its long-term cross-border capital strategy, made a notable impact this May at two of Asia's premier events: the Greenwich Economic Forum (GEF) Hong Kong and BEYOND Expo 2025 in Macau. At GEF Hong Kong, Reynold Lemkins Asia Chief Investment Officer Kris Haoran Liu was invited to speak on a high-level roundtable titled 'Family Office Investment Outlook', moderated by Tae Yoo, Managing Director of Hong Kong Exchanges and Clearing (HKEX). Liu emphasized IPO as not merely an exit but a strategic entry point into long-term value creation, especially in sectors undergoing structural transformation. He also highlighted Hong Kong's pivotal role as a pricing anchor for global capital. The forum, which brought together global financial leaders including Nouriel Roubini (Chairman & CEO, Roubini Macro Associates), Kenny Lam (CEO, Two Sigma Asia Pacific), and Jan Boomaars (CEO, Optiver), underscored the rising relevance of Asia—especially Hong Kong—in the evolving landscape of alternative investments, economic realignment, and tech-led growth. In Macau, at BEYOND Expo 2025 —Asia's largest tech innovation summit—Reynold Lemkins took part as a Legacy Partner, hosting private sessions with deep tech founders, researchers, and institutional LPs. The firm engaged across verticals including AI, advanced manufacturing, robotics, and frontier healthtech, reinforcing its thesis of value-backed, scalable innovation across borders. 'Reynold Lemkins Group demonstrated clear conviction in identifying globally relevant tech solutions, from regulatory-ready biotech platforms to next-gen energy systems and smart infrastructure,' commented a tech investor familiar with the firm's presence in Macau. Recent investments reflect this diversified thesis. In addition to health-focused companies like Cloudbreak Pharma and VISEN Pharmaceuticals, the firm has also actively supported high-growth industrial and AI ventures such as Contemporary Amperex Technology (CATL), Sanhua Intelligent Controls, and Unisound, exemplifying its multi-sector strategy across late-stage and semi-public market opportunities. To learn more, visit follow Reynold Lemkins on LinkedIn, or explore insights via Medium.
Yahoo
10-06-2025
- Business
- Yahoo
Backing the Future of Global Biotech: Reynold Lemkins' Strategy Across Borders and Stages
HONG KONG, June 10, 2025--(BUSINESS WIRE)--Reynold Lemkins Group, an international investment firm focused on value-driven cross-border capital deployment, announced the continued advancement of its strategic focus in late-stage healthcare, AI-powered therapeutics, and Asia-centered biotech commercialization. As part of this strategy, Reynold Lemkins recently participated in the IPO of VISEN Pharmaceuticals on the Hong Kong Stock Exchange (HKEX: 02561). VISEN, a biopharmaceutical company specializing in long-acting growth hormone therapies, attracted strong institutional demand and represents the kind of regulatory-validated, commercially scalable business the firm targets. Reynold Lemkins invested alongside globally recognized healthcare investors including HongShan Capital Group (previously Sequoia China), Sofinnova, Vivo Capital, OrbiMed, and WuXi Biologics (HKEX: 2269), reinforcing its commitment to cross-border innovation and long-term capital alignment. This investment underscores Reynold Lemkins' broader strategy of supporting science-driven, late-stage companies with scalable market potential—particularly those operating at the convergence of AI, therapeutics, and Asia-Pacific commercialization. "Our approach focuses on more than capital—we provide strategic insight and cross-border connectivity to help companies scale," said Kris Haoran Liu, President and Chief Investment Officer at Reynold Lemkins Group. "Biotech firms entering public markets need partners who understand both the science and the structure of global growth." With Asia playing an increasingly pivotal role in global healthcare, Reynold Lemkins sees a growing need for capital strategies that link scientific innovation with scalable regional execution. At the same time, the firm closely tracks trends in the U.S. and other mature markets, where biotech companies are navigating longer paths to liquidity and require strategic partners with global reach. Reynold Lemkins positions itself at this intersection—bridging East and West, public and private markets—to support companies shaping the next era of patient-centered care. To learn more, visit follow us on LinkedIn, or explore our insights on Medium. View source version on Contacts Reynold Lemkins Groupreynoldlemkins@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
10-06-2025
- Business
- Business Wire
Backing the Future of Global Biotech: Reynold Lemkins' Strategy Across Borders and Stages
HONG KONG--(BUSINESS WIRE)-- Reynold Lemkins Group, an international investment firm focused on value-driven cross-border capital deployment, announced the continued advancement of its strategic focus in late-stage healthcare, AI-powered therapeutics, and Asia-centered biotech commercialization. Bridging East and West in biotech investing, Reynold Lemkins backs science-driven companies with cross-border capital and global scale strategies. Share As part of this strategy, Reynold Lemkins recently participated in the IPO of VISEN Pharmaceuticals on the Hong Kong Stock Exchange (HKEX: 02561). VISEN, a biopharmaceutical company specializing in long-acting growth hormone therapies, attracted strong institutional demand and represents the kind of regulatory-validated, commercially scalable business the firm targets. Reynold Lemkins invested alongside globally recognized healthcare investors including HongShan Capital Group (previously Sequoia China), Sofinnova, Vivo Capital, OrbiMed, and WuXi Biologics (HKEX: 2269), reinforcing its commitment to cross-border innovation and long-term capital alignment. This investment underscores Reynold Lemkins' broader strategy of supporting science-driven, late-stage companies with scalable market potential—particularly those operating at the convergence of AI, therapeutics, and Asia-Pacific commercialization. 'Our approach focuses on more than capital—we provide strategic insight and cross-border connectivity to help companies scale,' said Kris Haoran Liu, President and Chief Investment Officer at Reynold Lemkins Group. 'Biotech firms entering public markets need partners who understand both the science and the structure of global growth.' With Asia playing an increasingly pivotal role in global healthcare, Reynold Lemkins sees a growing need for capital strategies that link scientific innovation with scalable regional execution. At the same time, the firm closely tracks trends in the U.S. and other mature markets, where biotech companies are navigating longer paths to liquidity and require strategic partners with global reach. Reynold Lemkins positions itself at this intersection—bridging East and West, public and private markets—to support companies shaping the next era of patient-centered care. To learn more, visit follow us on LinkedIn, or explore our insights on Medium.
